Evidence map›Paper›PMID 37195497›Full record

ArticleInflammopharmacology2024

Sjögren's syndrome.

Geza Balint, W Watson Buchanan, Colin A Kean, Walter Kean, K D Rainsford

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Geza Balint3rd Department of Rheumatology, National Institute of Rheumatology and Physiotherapy, Frankel Leó út 27-29, Budapest, 1023, Hungary.
W Watson BuchananDepartment of Medicine, McMaster University, Hamilton, ON, L8P 1H6, Canada.
Colin A KeanHaldimand War Memorial Hospital, 400 Broad Street, Dunnville, ON, N1A 2P7, Canada.
Walter KeanDepartment of Medicine, McMaster University, Hamilton, ON, L8P 1H6, Canada. wfkean@gmail.com.
K D RainsfordSheffield Hallam University, Sheffield, S1 1WB, UK.
McMaster University · CANational Institute of Oncology · HUSheffield Hallam University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sjögren's syndrome (SS) is characterised as keratoconjunctivitis sicca (dry eyes), xerostomia (dry mouth) commonly associated with salivary gland enlargement, and is referred to as Primary Sjögren's syndrome. It is known as Secondary Sjögren's syndrome when it occurs in patients, with connective tissue disease, such as rheumatoid arthritis, systemic lupus erythematosus, polyarthritis nodosa, polymyositis, and systemic sclerosis. SS has also been associated with chronic graft-versus-host disease after allogeneic bone marrow transplantation, human immunodeficiency syndrome (AIDS), hepatitis C infection (HCV), chronic biliary cirrhosis, neoplastic and myeloplastic syndromes, fibromyalgia, and chronic fatigue syndrome.

Indexed as

Arthritis, RheumatoidFibromyalgiaLupus Erythematosus, SystemicScleroderma, SystemicSjogren's SyndromeHumansConnective tissue diseaseDry eyesDry mouthKeratoconjunctivitis siccaSalivary gland enlargementXerostomia

Identifiers

PMID37195497
OpenAlexW4376871301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.